SOGROYA is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novo Nordisk. The primary component is Somapacitan.
| Product ID | 0169-2030_6c3b1f43-a9c6-445d-b82a-bbf2223857d6 | 
| NDC | 0169-2030 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | SOGROYA | 
| Generic Name | Somapacitan-beco | 
| Dosage Form | Injection, Solution | 
| Route of Administration | SUBCUTANEOUS | 
| Marketing Start Date | 2021-06-15 | 
| Marketing Category | BLA / | 
| Application Number | BLA761156 | 
| Labeler Name | Novo Nordisk | 
| Substance Name | SOMAPACITAN | 
| Active Ingredient Strength | 7 mg/mL | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2022-12-31 | 
| Marketing Start Date | 2021-06-15 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 0169-2030 | SOGROYA | somapacitan-beco | 
| 0169-2035 | SOGROYA | somapacitan-beco | 
Mark Image Registration | Serial  | Company  Trademark Application Date  | 
|---|---|
![]() SOGROYA  79262550  5934737 Live/Registered  | 
        Novo Nordisk Health Care AG  2019-05-24  |